Back to Clinical Trials

Brief Title: Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Participants With Muscle-invasive Bladder Cancer (MIBC) (KEYNOTE-992)

INTRODUCTION

  • Org Study ID: 3475-992
  • Secondary ID: MK-3475-992, 2019-004023-20, 205383
  • NTC ID: NCT04241185
  • Sponsor: Merck Sharp & Dohme Corp.

BRIEF SUMMARY

This study is designed to assess the antitumor efficacy and safety of pembrolizumab in combination with chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC). The primary hypothesis is that pembrolizumab + chemoradiotherapy is superior to placebo + chemoradiotherapy with respect to bladder intact event-free survival.

  • Overall Status
    Recruiting
  • Start Date
    May 19, 2020
  • Phase
    Phase 3
  • Study Type
    Interventional

PRIMARY OUTCOMES

Primary Outcome 1 - Measure: Bladder Intact Event-Free Survival (BI-EFS)

Primary Outcome 1 - Timeframe: Up to approximately 71 months

CONDITION

  • Urinary Bladder Neoplasms

ELIGIBILITY

Inclusion Criteria:
Has a histologically confirmed diagnosis of muscle-invasive bladder cancer (MIBC) with predominant urothelial histology

- Has clinically non-metastatic bladder cancer (N0M0)

- Has planned and is eligible to receive chemoradiotherapy (CRT) and one of the protocol-specified radiosensitizing chemotherapy regimens

- Has Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

- Demonstrates adequate organ function
Male participants are eligible to participate if they agree to the following during the intervention period and for at least 90 days after the last dose of CRT treatment:
Refrain from donating sperm

- Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent; or must agree to use contraception unless confirmed to be azoospermic
A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:
Is not a woman of childbearing potential (WOCBP)

- Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of <1% per year), with low user dependency or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis), during the intervention period and for at least 180 days the time needed to eliminate each study intervention after the last dose of study intervention; and agrees not to donate eggs (ova, oocytes) to others or freeze/store for her own use for the purpose of reproduction during this period. The length of time required to continue contraception for each study intervention is as follows: MK-3475 - 120 days and CRT - 180 days
Exclusion Criteria:
Has the presence of diffuse carcinoma in situ (CIS) (multiple foci of CIS) throughout the bladder

- Has the presence of urothelial carcinoma (UC) at any site outside of the urinary bladder in the previous 2 years except for Ta stage/T1 stage/CIS of the upper tract if the participant has undergone a complete nephroureterectomy

- Has a known additional malignancy that is progressing or has required active therapy within the past 3 years, except basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer or other carcinoma in situ that has undergone potentially curative therapy

- Has the presence of bilateral hydronephrosis

- Has limited bladder function with frequency of small amounts of urine (< 30 mL), urinary incontinence, or requires self-catheterization or a permanent indwelling catheter - Has received prior pelvic/local radiation therapy or any antineoplastic treatment for muscle-invasive bladder cancer (MIBC). Treatment for non-muscle invasive bladder cancer (NMIBC) with intravesical instillation therapy that was completed ≥28 days prior to randomization is allowed. Prior systemic treatment of NMIBC is not permitted. - Received prior therapy with an anti-PD-1 (programmed cell death protein 1), anti-PD-L1 (programmed death-ligand 1), or anti-PD-L2 (programmed cell death 1 ligand 2), or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4 [cytotoxic T-lymphocyte-associated protein 4], OX 40, or CD137 [cluster of differentiation 137]) - Has received a live vaccine within 30 days prior to the first dose of study drug - Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention - Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or the selected chemotherapy regimen, and/or any of their excipients - Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug - Has an active autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed - Has a history of non-infectious pneumonitis that required steroids or has current pneumonitis - Has an active infection requiring systemic therapy - Has a known history of human immunodeficiency virus (HIV) infection - Has a known history of Hepatitis B or known active Hepatitis C virus infection - Has a known history of active tuberculosis (TB; Bacillus tuberculosis) - Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study - Has had an allogenic tissue/solid organ transplant

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: Medical Director

Role: Study Director

Affiliation: Merck Sharp & Dohme Corp.

Overall Contact

Name: Medical Director

Phone: 1-888-577-8839

Email: Trialsites@merck.com

LOCATION

Facility Status Contact
Facility: Washington Cancer Institute at MedStar Washington Hospital Center ( Site 0041)
Washington, District of Columbia 20010
United States
Status: Recruiting Contact: Contact
Study Coordinator
202-877-9386
Facility: Bay Pines VA Medical Center ( Site 0055)
Bay Pines, Florida 33744
United States
Status: Recruiting Contact: Contact
Study Coordinator
727-398-6661
Facility: AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlando ( Site 0004)
Orlando, Florida 32804
United States
Status: Recruiting Contact: Contact
Study Coordinator
407-303-2024
Facility: Pikeville Medical Center ( Site 0009)
Pikeville, Kentucky 41501
United States
Status: Recruiting Contact: Contact
Study Coordinator
(410) 605-7000 x 4155
Facility: Baltimore VA Medical Center ( Site 0054)
Baltimore, Maryland 21201
United States
Status: Recruiting Contact: Contact
Study Coordinator
314-747-4328
Facility: Washington University ( Site 0003)
Saint Louis, Missouri 63110
United States
Status: Recruiting Contact: Contact
Study Coordinator
551-996-1379
Facility: John Theurer Cancer Center at Hackensack University Medical Center ( Site 0005)
Hackensack, New Jersey 07601
United States
Status: Recruiting Contact: Contact
Study Coordinator
518-489-3612
Facility: New York Oncology Hematology P.C ( Site 0024)
Albany, New York 12206
United States
Status: Recruiting Contact: Contact
Study Coordinator
516-289-3772
Facility: Winthrop University Hospital ( Site 0069)
Mineola, New York 11501
United States
Status: Recruiting Contact: Contact
Study Coordinator
212-731-6455
Facility: New York University Perlmutter Cancer Center ( Site 0001)
New York, New York 10016
United States
Status: Recruiting Contact: Contact
Study Coordinator
866-223-8100
Facility: Cleveland Clinic ( Site 0062)
Cleveland, Ohio 44195
United States
Status: Recruiting Contact: Contact
Study Coordinator
864-603-6213
Facility: Saint Francis Cancer Center ( Site 0026)
Greenville, South Carolina 29607
United States
Status: Recruiting Contact: Contact
Study Coordinator
843-449-1010 ext. 257
Facility: Carolina Urologic Research Center ( Site 0002)
Myrtle Beach, South Carolina 29572
United States
Status: Recruiting Contact: Contact
Study Coordinator
414-805-8900
Facility: Froedtert and Medical College of Wisconsin ( Site 0022)
Milwaukee, Wisconsin 53226
United States
Status: Recruiting Contact: Contact
Study Coordinator
61287389181
Facility: Liverpool Hospital ( Site 0220)
Liverpool, New South Wales 2170
Australia
Status: Recruiting Contact: Contact
Study Coordinator
61294631172
Facility: Northern Cancer Institute ( Site 0217)
St Leonards, New South Wales 2065
Australia
Status: Recruiting Contact: Contact
Study Coordinator
61436387664
Facility: Monash Health-Monash Medical Centre ( Site 0216)
Clayton, Victoria 3168
Australia
Status: Recruiting Contact: Contact
Study Coordinator
610420381848
Facility: Austin Health ( Site 0218)
Heidelberg, Victoria 3084
Australia
Status: Recruiting Contact: Contact
Study Coordinator
61893891437
Facility: Sir Charles Gairdner Hospital ( Site 0223)
Nedlands, Western Australia 6009
Australia
Status: Recruiting Contact: Contact
Study Coordinator
+420588444295
Facility: Fakultni nemocnice Olomouc ( Site 0559)
Olomouc, Hovedstaden 779 00
Czechia
Status: Recruiting Contact: Contact
Study Coordinator
+420266084516
Facility: 2. LF UK a FN Motol ( Site 0555)
Praha 5, Syddanmark 150 06
Czechia
Status: Recruiting Contact: Contact
Study Coordinator
+420266084441
Facility: Nemocnice Na Bulovce ( Site 0556)
Praha 8, Harjumaa 180 81
Czechia
Status: Recruiting Contact: Contact
Study Coordinator
4538683868
Facility: Herlev og Gentofte Hospital. ( Site 0401)
Herlev, Tartumaa 2730
Denmark
Status: Recruiting Contact: Contact
Study Coordinator
4566113333
Facility: Odense Universitetshospital ( Site 0403)
Odense, Provence-Alpes-Cote-d Azur 5000
Denmark
Status: Recruiting Contact: Contact
Study Coordinator
+3726172323
Facility: North Estonia Medical Centre Foundation ( Site 0081)
Tallin, Somme 13419
Estonia
Status: Recruiting Contact: Contact
Study Coordinator
+3727318815
Facility: Tartu University Hospital ( Site 0079)
Tartu, Bacs-Kiskun 51014
Estonia
Status: Recruiting Contact: Contact
Study Coordinator
+33490276090
Facility: Institut Sainte Catherine ( Site 0121)
Avignon, Borsod-Abauj-Zemplen 84918
France
Status: Recruiting Contact: Contact
Study Coordinator
+3332022087996
Facility: CHU Amiens Picardie Site Sud Amiens ( Site 0123)
Amiens, Gyor-Moson-Sopron 80000
France
Status: Recruiting Contact: Contact
Study Coordinator
+33172389445
Facility: Institut Curie ( Site 0112)
Paris, Lombardia 75005
France
Status: Recruiting Contact: Contact
Study Coordinator
+33140258935
Facility: A.P.H. Paris. Hopital Bichat Claude Bernard ( Site 0115)
Paris, Aomori 75018
France
Status: Recruiting Contact: Contact
Study Coordinator
+502 42142081
Facility: Centro de Investigaciones Clinicas de Latinoamerica S.A. - CELAN ( Site 0146)
Guatemala, Ibaraki 01010
Guatemala
Status: Recruiting Contact: Contact
Study Coordinator
50222781268
Facility: Oncomedica ( Site 0145)
Guatemala, Osaka 01010
Guatemala
Status: Recruiting Contact: Contact
Study Coordinator
+50223857572
Facility: Grupo Medico Angeles ( Site 0143)
Guatemala, Kyonggi-do 01015
Guatemala
Status: Recruiting Contact: Contact
Study Coordinator
+50223752222
Facility: Medi-K Cayala ( Site 0142)
Guatemala, Kyonggi-do 01016
Guatemala
Status: Recruiting Contact: Contact
Study Coordinator
+50259458053
Facility: Centro Medico Integral De Cancerología (CEMIC) ( Site 0144)
Quetzaltenango, Seoul 09002
Guatemala
Status: Recruiting Contact: Contact
Study Coordinator
+3676516719
Facility: Bacs-Kiskun Megyei Korhaz-Onkoradiologiai Kozpont ( Site 0095)
Kecskemét, Taejon-Kwangyokshi 6000
Hungary
Status: Recruiting Contact: Contact
Study Coordinator
+3646515200
Facility: BAZ Megyei Korhaz. Klinikai Onkologia es Sugarterapias Centrum ( Site 0092)
Miskolc, Kelantan 3526
Hungary
Status: Recruiting Contact: Contact
Study Coordinator
+3696507900
Facility: Petz Aladar Megyei Oktato Korhaz ( Site 0099)
Gyor, Pulau Pinang 9024
Hungary
Status: Recruiting Contact: Contact
Study Coordinator
+3652255585
Facility: Debreceni Egyetem Klinikai Kozpont ( Site 0097)
Debrecen, Noord-Holland 4032
Hungary
Status: Recruiting Contact: Contact
Study Coordinator
+36306554043
Facility: Somogy Megyei Kaposi Mor Oktato Korhaz ( Site 0091)
Kaposvar, Zuid-Holland 7400
Hungary
Status: Recruiting Contact: Contact
Study Coordinator
+97247773811
Facility: Rambam Medical Center ( Site 0088)
Haifa, Malopolskie 1834111
Israel
Status: Recruiting Contact: Contact
Study Coordinator
+97226776760
Facility: Hadassah Medical Center. Ein Kerem ( Site 0086)
Jerusalem, Zachodniopomorskie 9112001
Israel
Status: Recruiting Contact: Contact
Study Coordinator
+97235302542
Facility: Chaim Sheba Medical Center ( Site 0087)
Ramat Gan, Cluj 5262000
Israel
Status: Recruiting Contact: Contact
Study Coordinator
+97236973413
Facility: Sourasky Medical Center ( Site 0089)
Tel Aviv, Cluj 6423906
Israel
Status: Recruiting Contact: Contact
Study Coordinator
+390226435668
Facility: Ospedale San Raffaele ( Site 0194)
Milano, Dolj 20132
Italy
Status: Recruiting Contact: Contact
Study Coordinator
+390805555355
Facility: IRCCS Giovanni Paolo II. Ospedale Oncologico ( Site 0193)
Bari, Timis 70124
Italy
Status: Recruiting Contact: Contact
Study Coordinator
+390557947019
Facility: AOU Careggi ( Site 0191)
Firenze, Barcelona 50134
Italy
Status: Recruiting Contact: Contact
Study Coordinator
+3907332572881
Facility: Ospedale Civile di Macerata ( Site 0190)
Macerata, Valenciana, Comunitat 62100
Italy
Status: Recruiting Contact: Contact
Study Coordinator
+390223903818
Facility: Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 0186)
Milano, Dnipropetrovska Oblast 20133
Italy
Status: Recruiting Contact: Contact
Study Coordinator
+390594224767
Facility: Azienda Ospedaliero - Universitaria Policlinico di Modena ( Site 0188)
Modena, Kharkivska Oblast 41124
Italy
Status: Recruiting Contact: Contact
Study Coordinator
+390815903637
Facility: Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 0192)
Napoli, Kharkivska Oblast 80131
Italy
Status: Recruiting Contact: Contact
Study Coordinator
+81172335111
Facility: Hirosaki University Hospital ( Site 0602)
Hirosaki, Kirovohradska Oblast 036-8563
Japan
Status: Recruiting Contact: Contact
Study Coordinator
+81298533900
Facility: University of Tsukuba Hospital ( Site 0605)
Tsukuba, Kyivska Oblast 305-8576
Japan
Status: Recruiting Contact: Contact
Study Coordinator
+81726831221
Facility: Osaka Medical and Pharmaceutical University Hospital ( Site 0604)
Takatsuki, Kyivska Oblast 569-8686
Japan
Status: Recruiting Contact: Contact
Study Coordinator
+81958197200
Facility: Nagasaki University Hospital ( Site 0600)
Nagasaki, Denbighshire 852-8501
Japan
Status: Recruiting Contact: Contact
Study Coordinator
+81338136111
Facility: Medical Hospital, Tokyo Medical And Dental University ( Site 0601)
Tokyo, Devon 113-8519
Japan
Status: Recruiting Contact: Contact
Study Coordinator
+81-3-3823-2101
Facility: Tokyo Metropolitan Komagome Hospital ( Site 0606)
Tokyo, London, City Of 113-8677
Japan
Status: Recruiting Contact: Contact
Study Coordinator
+82319203679
Facility: National Cancer Center ( Site 0202)
Gyeonggi-do, London, City Of 10408
Korea, Republic of
Status: Recruiting Contact: Contact
Study Coordinator
+82317877071
Facility: Seoul National University Bundang Hospital ( Site 0204)
Seongnam-si, Nottinghamshire 13620
Korea, Republic of
Status: Recruiting Contact: Contact
Study Coordinator
+82230105614
Facility: Asan Medical Center ( Site 0200)
Songpagu, 05505
Korea, Republic of
Status: Recruiting Contact: Contact
Study Coordinator
+82422808369
Facility: Chungnam National University Hospital ( Site 0203)
Daejeon, 35015
Korea, Republic of
Status: Recruiting Contact: Contact
Study Coordinator
+8229206267
Facility: Korea University Anam Hospital ( Site 0205)
Seoul, 02841
Korea, Republic of
Status: Recruiting Contact: Contact
Study Coordinator
+82222288138
Facility: Severance Hospital Yonsei University Health System ( Site 0201)
Seoul, 03722
Korea, Republic of
Status: Recruiting Contact: Contact
Study Coordinator
+37129262596
Facility: Pauls Stradins Clinical University Hospital ( Site 0073)
Riga, 1002
Latvia
Status: Recruiting Contact: Contact
Study Coordinator
+6097676684
Facility: Hospital Universiti Sains Malaysia ( Site 0237)
Kubang Kerian, 16150
Malaysia
Status: Recruiting Contact: Contact
Study Coordinator
+6042225768
Facility: Hospital Pulau Pinang ( Site 0239)
Penang, 10990
Malaysia
Status: Recruiting Contact: Contact
Study Coordinator
+60326155810
Facility: Hospital Kuala Lumpur ( Site 0238)
Kuala Lumpur, 50586
Malaysia
Status: Recruiting Contact: Contact
Study Coordinator
+60379492120
Facility: University Malaya Medical Centre ( Site 0236)
Kuala Lumpur, 59100
Malaysia
Status: Recruiting Contact: Contact
Study Coordinator
+31205122569
Facility: Netherlands Cancer Institute (NKI) ( Site 0183)
Amsterdam, 1066 CX
Netherlands
Status: Recruiting Contact: Contact
Study Coordinator
+31107041505
Facility: Erasmus MC ( Site 0182)
Rotterdam, 3015 GD
Netherlands
Status: Recruiting Contact: Contact
Study Coordinator
48606751459
Facility: Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie ( Site 0153)
Krakow, 31-826
Poland
Status: Recruiting Contact: Contact
Study Coordinator
+48943488931
Facility: Szpital Wojewodzki im. Mikolaja Kopernika ( Site 0152)
Koszalin, 75-581
Poland
Status: Recruiting Contact: Contact
Study Coordinator
+351210431703
Facility: CHLO, EPE - Hospital de Sao Francisco Xavier ( Site 0302)
Lisboa, 1449-005
Portugal
Status: Recruiting Contact: Contact
Study Coordinator
+351217805000
Facility: Centro Hospitalar Lisboa Norte EPE - Hospital de Santa Maria ( Site 0305)
Lisboa, 1649-035
Portugal
Status: Recruiting Contact: Contact
Study Coordinator
7872843333
Facility: Advance Urology and Laparoscopic Center ( Site 0281)
Ponce, 00716
Puerto Rico
Status: Recruiting Contact: Contact
Study Coordinator
7874073333
Facility: PAN American Center Oncologic ( Site 0280)
San Juan, Rio Piedras, 00935
Puerto Rico
Status: Recruiting Contact: Contact
Study Coordinator
+40745976913
Facility: Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 0249)
Cluj Napoca, 400015
Romania
Status: Recruiting Contact: Contact
Study Coordinator
+40742206212
Facility: S.C. Radiotherapy Center Cluj S.R.L ( Site 0252)
Cluj-Napoca, 407280
Romania
Status: Recruiting Contact: Contact
Study Coordinator
+40727774974
Facility: S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 0248)
Craiova, 200347
Romania
Status: Recruiting Contact: Contact
Study Coordinator
+40745100495
Facility: Policlinica Oncomed SRL ( Site 0254)
Timisoara, 300239
Romania
Status: Recruiting Contact: Contact
Study Coordinator
+40374278811
Facility: Institutul Regional de Oncologie Iasi ( Site 0255)
Iasi, 700483
Romania
Status: Recruiting Contact: Contact
Study Coordinator
+34932607744
Facility: Instituto Catalan de Oncologia - ICO ( Site 0103)
L Hospitalet De Llobregat, 08908
Spain
Status: Recruiting Contact: Contact
Study Coordinator
+34961244188
Facility: Hospital La Fe de Valencia ( Site 0105)
Valencia, 46026
Spain
Status: Recruiting Contact: Contact
Study Coordinator
88677317123
Facility: Kaohsiung Chang Gung Memorial Hospital ( Site 0209)
Kaohsiung, 83301
Taiwan
Status: Recruiting Contact: Contact
Study Coordinator
88662353535
Facility: National Cheng Kung University Hospital ( Site 0208)
Tainan, 704
Taiwan
Status: Recruiting Contact: Contact
Study Coordinator
+886223123456
Facility: National Taiwan University Hospital ( Site 0210)
Taipei, 10002
Taiwan
Status: Recruiting Contact: Contact
Study Coordinator
+886228757519304
Facility: Taipei Veterans General Hospital ( Site 0211)
Taipei, 11217
Taiwan
Status: Recruiting Contact: Contact
Study Coordinator
+886 3-3281200 ext8825
Facility: Chang Gung Medical Foundation.Linkou Branch ( Site 0212)
Taoyuan, 333
Taiwan
Status: Recruiting Contact: Contact
Study Coordinator
+905337483275
Facility: Ankara Universitesi Tip Fakultesi. ( Site 0502)
Ankara, 06100
Turkey
Status: Recruiting Contact: Contact
Study Coordinator
+905333682319
Facility: Istanbul Uni. Cerrahpasa Tip Fakultesi ( Site 0501)
Istanbul, 34098
Turkey
Status: Recruiting Contact: Contact
Study Coordinator
+905063509061
Facility: Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi-oncology ( Site 0504)
Istanbul, 34722
Turkey
Status: Recruiting Contact: Contact
Study Coordinator
+905337360674
Facility: Ege University Medical Faculty ( Site 0508)
Izmir, 35100
Turkey
Status: Recruiting Contact: Contact
Study Coordinator
+905052180361
Facility: Karadeniz Teknik Universitesi Tip Fakultesi ( Site 0503)
Trabzon, 61080
Turkey
Status: Recruiting Contact: Contact
Study Coordinator
+80687400930
Facility: Clinical oncology dispensary of Dnipro ( Site 0133)
Dnipro, 49055
Ukraine
Status: Recruiting Contact: Contact
Study Coordinator
+380669906870
Facility: Grigoriev Institute for medical Radiology NAMS of Ukraine ( Site 0139)
Kharkiv, 61024
Ukraine
Status: Recruiting Contact: Contact
Study Coordinator
+380508266088
Facility: CNPE "Regional Center of Oncology" ( Site 0134)
Kharkiv, 61070
Ukraine
Status: Recruiting Contact: Contact
Study Coordinator
+380979428527
Facility: Ukranian Center of TomoTherapy ( Site 0140)
Kropyvnytskiy, 25011
Ukraine
Status: Recruiting Contact: Contact
Study Coordinator
+380672365175
Facility: National Cancer Institute of the MoH of Ukraine ( Site 0136)
Kyiv, 03022
Ukraine
Status: Recruiting Contact: Contact
Study Coordinator
+380667027558
Facility: Kyiv City Clinical Oncology Center ( Site 0135)
Kyiv, 03115
Ukraine
Status: Recruiting Contact: Contact
Study Coordinator
+441745445231
Facility: Betsi Cadwaladr University Health Board ( Site 0447)
Rhyl, LL18 5UJ
United Kingdom
Status: Recruiting Contact: Contact
Study Coordinator
+441803614567
Facility: South Devon Healthcare Foundation Trust. Torbay Hospital ( Site 0444)
Torquay, TQ2 7AA
United Kingdom
Status: Recruiting Contact: Contact
Study Coordinator
+4420 3456 7014
Facility: University College London Hospitals NHS Foundation Trust ( Site 0445)
London, NW1 2PG
United Kingdom
Status: Recruiting Contact: Contact
Study Coordinator
+442078082788
Facility: The Royal Marsden NHS Foundation Trust. ( Site 0442)
London, SW3 6JJ
United Kingdom
Status: Recruiting Contact: Contact
Study Coordinator
+441159691169 x71985
Facility: Nottingham University Hospital NHS Trust ( Site 0250)
Nottingham, NG5 1PB
United Kingdom
Status: Recruiting Contact: N/A